Drug combination study for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has returned or spread and failed first-line treatment with cisplatin-based therapy
- You are between 18 and 70 years old
- You are physically active enough to care for yourself (ECOG 0-1)
- You have a tumor that can be measured on scans (not just in bone)
- You are willing to provide a tumor sample for testing
- Your blood counts and liver/kidney function are within a safe range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs and radiation for advanced nasopharyngeal cancer. It aims to improve outcomes by adding a type of immunotherapy and an omega-3 supplement to standard treatment.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
This study tests two immunotherapy drugs together for people whose nasopharyngeal cancer has continued to grow after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer. The goal is to see if adding these drugs improves the chances of controlling the cancer.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.